Statements |
Answer (n, % agreement) |
Reached consensus at round |
Statement 23 |
For patients on IFN-b, it may be considered safe to continue treatment during pregnancy and lactation if it is clinically necessary. |
Agree (42,97,6%) |
1º |
Statement 24 |
DMF and glatiramer acetate should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. |
|
Not reached |
Statement 25 |
Would you maintain glatiramer acetate throughout the pregnancy in a treated patient with a controlled disease? |
No (29, 72,5%) |
3º |
Statement 26 |
In highly active patients, alemtuzumab and cladribine could facilitate family planning, pregnancy, and breastfeeding, due to their pharmacologic characteristics. |
Agree (42,97,6%) |
1º |
Statement 27 |
In patients on alemtuzumab, the risks of potentially serious adverse effects on the fetus due to drug-associated secondary autoimmunity problems should be considered. |
Agree (32, 74,4%) |
1º |
Statement 28 |
In highly active MS patients, the possibility of withholding DMT treatment throughout the pregnancy should be considered. |
Agree (35, 81,4%) |
1º |
Statement 29 |
In case of relapses during pregnancy and its possible treatments: |
a.- It is recommended to use intravenous methylprednisolone and prednisolone, whereas dexamethasone is contraindicated. |
Agree (33, 76,7%) |
1º |
b.- The use of plasmapheresis or immunoglobulins may be considered if clinically necessary. |
Agree (40, 93%) |
1º |
c.- A case of a mild relapse, could not be treated. |
Agree (37, 86%) |
1º |
d.- If there is a relapse, corticosteroids should be used after the second trimester. |
|
Not reached |
e.- In case of disabling relapses, would you recommend treating it with immunoglobulins? |
|
Not reached |
f.- In case of disabling relapses, would you recommend treating it with plasmapheresis? |
Yes 34 (80,1%) |
2º |
Statement 30 |
Patients with MS can receive epidural anesthesia and can deliver just like any woman unaffected by MS. |
Agree 43, 100% |
1º |
Statement 31 |
In a patient with very active MS, would you maintain natalizumab during pregnancy? |
Yes (39, 97,5%) |
º |